Evidence map›Paper›PMID 42621469›Full record

ArticleACS medicinal chemistry letters2026

Discovery of VU6052959/BI'7927: A Selective mGlu

Caleb A Jones, Renn A Duncan, Kristen M Gilliland, Daniel H Haymer, Paul K Spearing, Rory A Capstick, Bartholomew P Roland, Paige Vinson, Marc Quitalig, Caroline Baggeroer and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Caleb A JonesWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID https://orcid.org/0000-0002-0471-9392
Renn A DuncanWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Kristen M GillilandWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Daniel H HaymerWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Paul K SpearingWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Rory A CapstickWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Bartholomew P RolandWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID https://orcid.org/0000-0002-9033-9942
Paige VinsonWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Marc QuitaligWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Caroline BaggeroerWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Natasha B BillardWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Jonathan W DickersonWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Katherine J WatsonWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Valerie M KramlingerWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Olivier BoutaudWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Daniel UrsuBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach, Germany.
Carsten T WotjakBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach, Germany.
Henning PriepkeBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach, Germany.
Michel GarneauBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach, Germany.
Kristina TrenzBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach, Germany.
Colleen M NiswenderWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID https://orcid.org/0000-0001-6009-8212
Hyekyung P ChoWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Jerri M RookWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Matthias FreiwaldBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach, Germany.
Riccardo GiovanniniBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach, Germany.
Heiko SommerBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach, Germany.
Scott HobsonBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach, Germany.
P Jeffrey ConnWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Bruce J MelanconWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.
Craig W LindsleyWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID https://orcid.org/0000-0003-0168-1445
Carson W ReedWarren Center for Neuroscience Drug Discovery, Vanderbilt Institute for Therapeutic Advances, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID https://orcid.org/0000-0002-9172-2847

Funding

Discovery of mGlu receptor PAMs for treatment of schizophreniaR01MH119673 · NIMH · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2019 to 2023
$3.6M
NIMH NIH HHS R01 MH119673
6 · The paper itself

Abstract

We report the discovery of an additional selective metabotropic glutamate receptor subtype 3 (mGlu

Indexed as

cognitionmetabolismmetabotropic glutamate receptor subtype 3mGlu3novel object recognitionPAMpharmacokineticspositive allosteric modulator

Identifiers

PMID42621469
PMCPMC13488376

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.